{"title":"比较阿莫西林和曲美普林:防治大肠埃希菌引起的尿路感染的总体效果","authors":"Yiou Teng","doi":"10.54254/2753-8818/44/20240578","DOIUrl":null,"url":null,"abstract":"Urinary Tract Infection (UTI) is one of the most prevalent bacterial infections in the world, and 80% of reported UTI cases are derived by gram negative bacteria Escherichia coli. Uropathogenic Escherichia coli is strongly adaptive and resilient against immune response, forming Intracellular Bacterial Communities (IBC) inside uroepithelium cells that constitute the urethra and the bladder. Their rapid absorption of cellular nutrients enables them to advance upward toward the kidney and cause inflammation. Hence, based on the perceived severity of UTI, multiple antibiotics are used to treat UPEC-causing UTI. This article provides a detailed review on the contemporary performance of amoxicillin and trimethoprim, both widely used to treat UPEC-causing UTI for decades. Amoxicillin is a penicillin-derivative that produces bactericidal by inhibiting transpeptidase to disrupt peptidoglycan synthesis, causing rapid-growing bacteria to lyse. It is a well-tolerated drug that can be used on pregnant patients. Resistant UPEC develop beta-lactamase to counter amoxicillin. Trimethoprim, on the other hand, is a dihydropyrimidine antibiotic that impedes the production of tetrahydrofolic acids, producing either bacteriostatic or bactericidal effects. Resistant UPEC transforms the shape of tetrahydrofolic acids-producing enzyme, dihydrofolic reductase, to resist trimethoprim. Although amoxicillin and trimethoprim are competitive inhibitors are effective against a variety of gram-positive and gram-negative species, trimethoprim, in statistical study, is proven to be more effective than amoxicillin in treating gram-negative UTI. Today, the wide-spread resistant strains of UPEC exists for both drugs. Thus, amoxicillin and trimethoprim are implemented mainly through combination therapies, amoxicillin/clavulanate and trimethoprim sulfamethoxazole, respectively. These combinations are more effective than the drugs to be used alone and are able to counter some resistant strains, but UPEC that are resistant to combinations also exists. Regardless, both amoxicillin and trimethoprim are still used as first-line antibiotics, while more powerful antibiotics are reserved for special multi-resistant superbugs.","PeriodicalId":341023,"journal":{"name":"Theoretical and Natural Science","volume":"24 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparing amoxicillin and trimethoprim: Overall performance in combating Escherichia coli-causing urinary tract infection\",\"authors\":\"Yiou Teng\",\"doi\":\"10.54254/2753-8818/44/20240578\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Urinary Tract Infection (UTI) is one of the most prevalent bacterial infections in the world, and 80% of reported UTI cases are derived by gram negative bacteria Escherichia coli. Uropathogenic Escherichia coli is strongly adaptive and resilient against immune response, forming Intracellular Bacterial Communities (IBC) inside uroepithelium cells that constitute the urethra and the bladder. Their rapid absorption of cellular nutrients enables them to advance upward toward the kidney and cause inflammation. Hence, based on the perceived severity of UTI, multiple antibiotics are used to treat UPEC-causing UTI. This article provides a detailed review on the contemporary performance of amoxicillin and trimethoprim, both widely used to treat UPEC-causing UTI for decades. Amoxicillin is a penicillin-derivative that produces bactericidal by inhibiting transpeptidase to disrupt peptidoglycan synthesis, causing rapid-growing bacteria to lyse. It is a well-tolerated drug that can be used on pregnant patients. Resistant UPEC develop beta-lactamase to counter amoxicillin. Trimethoprim, on the other hand, is a dihydropyrimidine antibiotic that impedes the production of tetrahydrofolic acids, producing either bacteriostatic or bactericidal effects. Resistant UPEC transforms the shape of tetrahydrofolic acids-producing enzyme, dihydrofolic reductase, to resist trimethoprim. Although amoxicillin and trimethoprim are competitive inhibitors are effective against a variety of gram-positive and gram-negative species, trimethoprim, in statistical study, is proven to be more effective than amoxicillin in treating gram-negative UTI. Today, the wide-spread resistant strains of UPEC exists for both drugs. Thus, amoxicillin and trimethoprim are implemented mainly through combination therapies, amoxicillin/clavulanate and trimethoprim sulfamethoxazole, respectively. These combinations are more effective than the drugs to be used alone and are able to counter some resistant strains, but UPEC that are resistant to combinations also exists. Regardless, both amoxicillin and trimethoprim are still used as first-line antibiotics, while more powerful antibiotics are reserved for special multi-resistant superbugs.\",\"PeriodicalId\":341023,\"journal\":{\"name\":\"Theoretical and Natural Science\",\"volume\":\"24 10\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Theoretical and Natural Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54254/2753-8818/44/20240578\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Theoretical and Natural Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54254/2753-8818/44/20240578","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
尿路感染(UTI)是世界上最常见的细菌感染之一,80%的UTI病例都是由革兰氏阴性大肠杆菌引起的。尿路致病性大肠埃希菌具有很强的适应性和抗免疫反应能力,可在构成尿道和膀胱的尿路上皮细胞内形成胞内细菌群落(IBC)。它们能迅速吸收细胞营养,并向上推进至肾脏,引发炎症。因此,根据UTI的严重程度,多种抗生素被用于治疗由UPEC引起的UTI。本文详细回顾了阿莫西林和三甲氧苄氨嘧啶的当代表现,这两种抗生素几十年来一直被广泛用于治疗引起 UTI 的 UPEC。阿莫西林是一种青霉素衍生物,通过抑制转肽酶破坏肽聚糖合成产生杀菌作用,使快速生长的细菌溶解。它是一种耐受性良好的药物,可用于孕妇。耐药的 UPEC 会产生β-内酰胺酶来对抗阿莫西林。甲氧苄啶则是一种二氢嘧啶类抗生素,可阻碍四氢叶酸的产生,产生抑菌或杀菌作用。耐药的 UPEC 会改变产生四氢叶酸的酶--二氢叶酸还原酶的形状,以抵抗曲美普林。虽然阿莫西林和曲美普林是竞争性抑制剂,对多种革兰氏阳性和革兰氏阴性菌有效,但统计研究证明,曲美普林在治疗革兰氏阴性尿路感染方面比阿莫西林更有效。如今,UPEC 的耐药菌株广泛存在于这两种药物中。因此,阿莫西林和曲美普林主要通过联合疗法(分别为阿莫西林/克拉维酸和曲美普林-磺胺甲噁唑)进行治疗。这些联合疗法比单独使用药物更有效,能够对付一些耐药菌株,但也存在对联合疗法耐药的 UPEC。无论如何,阿莫西林和三甲氧苄氨嘧啶仍被用作一线抗生素,而更强效的抗生素则留给了特殊的多重耐药性超级细菌。
Comparing amoxicillin and trimethoprim: Overall performance in combating Escherichia coli-causing urinary tract infection
Urinary Tract Infection (UTI) is one of the most prevalent bacterial infections in the world, and 80% of reported UTI cases are derived by gram negative bacteria Escherichia coli. Uropathogenic Escherichia coli is strongly adaptive and resilient against immune response, forming Intracellular Bacterial Communities (IBC) inside uroepithelium cells that constitute the urethra and the bladder. Their rapid absorption of cellular nutrients enables them to advance upward toward the kidney and cause inflammation. Hence, based on the perceived severity of UTI, multiple antibiotics are used to treat UPEC-causing UTI. This article provides a detailed review on the contemporary performance of amoxicillin and trimethoprim, both widely used to treat UPEC-causing UTI for decades. Amoxicillin is a penicillin-derivative that produces bactericidal by inhibiting transpeptidase to disrupt peptidoglycan synthesis, causing rapid-growing bacteria to lyse. It is a well-tolerated drug that can be used on pregnant patients. Resistant UPEC develop beta-lactamase to counter amoxicillin. Trimethoprim, on the other hand, is a dihydropyrimidine antibiotic that impedes the production of tetrahydrofolic acids, producing either bacteriostatic or bactericidal effects. Resistant UPEC transforms the shape of tetrahydrofolic acids-producing enzyme, dihydrofolic reductase, to resist trimethoprim. Although amoxicillin and trimethoprim are competitive inhibitors are effective against a variety of gram-positive and gram-negative species, trimethoprim, in statistical study, is proven to be more effective than amoxicillin in treating gram-negative UTI. Today, the wide-spread resistant strains of UPEC exists for both drugs. Thus, amoxicillin and trimethoprim are implemented mainly through combination therapies, amoxicillin/clavulanate and trimethoprim sulfamethoxazole, respectively. These combinations are more effective than the drugs to be used alone and are able to counter some resistant strains, but UPEC that are resistant to combinations also exists. Regardless, both amoxicillin and trimethoprim are still used as first-line antibiotics, while more powerful antibiotics are reserved for special multi-resistant superbugs.